rss
Br J Ophthalmol 2001;85:921-924 doi:10.1136/bjo.85.8.921
  • Scientific correspondence

Ocular hypotensive efficacy and safety of once daily carteolol alginate

  1. Philippe Demaillya,
  2. Catherine Allaireb,
  3. Claude Trinquand for the Once-daily Carteolol Study Groupb
  1. aHôpital St Joseph, Institut du Glaucome, Paris, France, bScientific and Medical Affairs Department, Laboratoire Chauvin, Montpellier, France
  1. Claude Trinquand, MD, Laboratoire Chauvin, Scientific and Medical Affairs Department, Le Millenaire, BP 1174, F-34009 Montpellier cedex, Francectrinqua{at}chauvingroup.com
  • Accepted 6 March 2001

Abstract

BACKGROUND/AIM Carteolol is a β adrenoceptor antagonist used topically to reduce intraocular pressure, typically twice daily. In an effort to provide a once daily dosing regimen, carteolol was formulated with 1% alginic acid. The objective of this study was to evaluate the efficacy and safety of carteolol alginate solution in comparison with standard carteolol solution.

METHODS This was a double masked, parallel group, multicentre study. Patients with ocular hypertension or open angle glaucoma (n=235) were randomly assigned to receive either carteolol alginate four times daily or standard carteolol solution, twice daily. The masking was maintained through the use of a vehicle in the evening for the alginate group. Patients were evaluated at baseline, 15, 60, and 120 days.

RESULTS At 0900 (presumed trough) on day 60, mean reductions in intraocular pressure (IOP) from baseline were 6.09 (SD 2.97) and 6.09 (3.18) mm Hg for the standard carteolol and alginate, respectively. At 1100 (presumed peak), mean reductions were 6.51 (2.53) and 6.47 (2.76) mm Hg, respectively. Results were similar at other times (day 15 and day 120). The most common side effect was transient stinging on instillation of drops, which did not differ significantly between groups. There were no differences of note in other ocular or systemic signs or symptoms.

CONCLUSION The new alginate formulation of carteolol 2% given once daily was as effective as standard carteolol 2% given twice daily with no meaningful differences regarding safety.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.